Why is Amgen stock sliding today?

Amgen shares fell 2.2% to $382.67 after HSBC downgraded the stock to Hold from Buy and cut its target to $425 from $445, following BMO's downgrade earlier in the week. Investors are reassessing olpasiran after Novartis's Phase III Lp(a) drug failure, while HSBC expects patent expiries to limit Amgen revenue growth to low single digits and sees key pipeline catalysts as back-ended to late 2027. Positive Phase III survival data for Imdelltra supported reaffirmed Buy ratings from William Blair and Piper Sandler, but did not offset the pipeline and regulatory concerns; the stock remains well below its $447.03 52-week high.

Analysis

The key equity issue is not the single-day downgrade but a probable reset in Amgen’s pipeline probability-of-success assumptions. OCEAN(a) had been a potential late-decade growth bridge against erosion in the legacy portfolio; a negative cardiovascular-outcomes read-through could force investors to value it closer to an R&D option than a revenue contributor. That raises the risk of multiple compression over the next 1-3 months as sell-side models revisit terminal-growth assumptions, even if near-term EPS remains intact.

The market may be overgeneralizing the Lp(a) result across distinct modalities and trial designs, creating an important distinction between a class warning and a definitive failure of olpasiran. Amgen’s downside is therefore more likely to be valuation-driven than an immediate earnings impairment. A credible management explanation of sustained Lp(a) reduction, patient selection, or endpoint differentiation could trigger a sharp relief rally; conversely, any delay, redesign, or reduced confidence around OCEAN(a) would remove a material portion of the long-duration growth case.

Imdelltra is the nearer monetization offset, but oncology uptake must now do more work to support estimates while obesity and cardiovascular assets remain back-end loaded. The relevant confirmation points are prescription/launch metrics for Imdelltra, 2026-27 revenue guidance, and whether management changes its framing of olpasiran’s probability of success. The UK issue appears financially secondary unless it broadens into additional regulatory scrutiny or materially disrupts a higher-margin rare-disease franchise.

Key Decisions for Investors

• Tactically underweight AMGN for 1-3 months; maintain a short only below $400, with a close above $400 following management reaffirmation of OCEAN(a) timing and differentiated efficacy as the thesis invalidation signal. Initial downside objective is $350-$360, where the post-event valuation reset should be reassessed.
• For defined risk, buy AMGN 3-month $380/$340 put spreads only if implied volatility is not already elevated versus its one-year range; the trade targets continued estimate and probability-of-success cuts while limiting exposure to a clinical-mechanism relief rally.
• Use a relative-value expression rather than broad biotech beta: short AMGN versus long a diversified large-cap pharma proxy such as XLV or a basket led by LLY/MRK, sized beta-neutral. This isolates Amgen’s pipeline-duration and patent-cliff exposure from defensive healthcare flows during macro volatility.
• Do not short NVS solely as a sympathy trade: its pipeline disappointment is likely already more fully reflected, while Amgen still faces a forward revision cycle. Revisit the AMGN short after the next investor presentation or earnings call; explicit disclosure that olpasiran economics are excluded from long-range guidance would be a bearish catalyst, while a quantified favorable differentiation case would warrant covering.